Format

Send to

Choose Destination
Curr Diab Rep. 2016 Aug;16(8):70. doi: 10.1007/s11892-016-0764-0.

Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes?

Author information

1
Section of Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center and Harvard Medical School, Boston, MA, 02215, USA.
2
Division of Endocrinology, Department of Medicine, Boston Children's Hospital, Boston, MA, 02215, USA.
3
Section of Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center and Harvard Medical School, Boston, MA, 02215, USA. Rohit.Kulkarni@joslin.harvard.edu.
4
Harvard Stem Cell Institute, Boston, MA, 02215, USA. Rohit.Kulkarni@joslin.harvard.edu.

Abstract

Diabetes is a progressive disease affecting millions of people worldwide. There are several medications and treatment options to improve the life quality of people with diabetes. One of the strategies for the treatment of diabetes could be the use of human pluripotent stem cells or induced pluripotent stem cells. The recent advances in differentiation of stem cells into insulin-secreting beta-like cells in vitro make the transplantation of the stem cell-derived beta-like cells an attractive approach for treatment of type 1 and type 2 diabetes. While stem cell-derived beta-like cells provide an unlimited cell source for beta cell replacement therapies, these cells can also be used as a platform for drug screening or modeling diseases.

KEYWORDS:

Diabetes; Differentiation; Human pluripotent stem cells; Induced pluripotent stem cells; Pancreatic beta cells

PMID:
27313072
PMCID:
PMC5877461
DOI:
10.1007/s11892-016-0764-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center